Search results for "Topic"

showing 10 items of 2844 documents

International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (r…

2017

Autoimmune diseases are a complex set of diseases characterized by immune system activation and, although many progresses have been done in the last 15 years, several unmet needs in the management of these patients may be still identified. Recently, a panel of international Experts, divided in different working groups according to their clinical and scientific expertise, were asked to identify, debate and formulate a list of key unmet needs within the field of rheumatology, serving as a roadmap for research as well as support for clinicians. After a systematic review of the literature, the results and the discussions from each working group were summarised in different statements. Due to th…

0301 basic medicineQuality managementEffectivenesslaw.inventionSystemic sclerosi0302 clinical medicineAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Immunology and Allergy; ImmunologylawAntiphospholipid syndromeImmunology and AllergyDisease management (health)ComputingMilieux_MISCELLANEOUSSpondyloarthritideClinical Trials as TopicEffectiveneDisease ManagementQuality Improvement3. Good healthSjogren's syndromeRheumatoid arthritis[SDV.IMM]Life Sciences [q-bio]/ImmunologySystemic sclerosisUnmet needmedicine.medical_specialtyRemissionImmunologyAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs;Systemic lupus erythematosuUnmet needs; rheumatoid arthritis; spondyloarthritides;Unmet needsNOAutoimmune Diseases03 medical and health sciencesSystemic lupus erythematosusAntiphospholipid syndromeInternal medicineRheumatic DiseasesmedicineHumansRheumatoid arthritisIntensive care medicineRheumatoid arthriti030203 arthritis & rheumatologyAutoimmune diseasetherapybusiness.industryAntiphospholipid syndrome; Biologic drugs treatment; Effectiveness; Remission; Rheumatoid arthritis; Sjogren's syndrome; Spondyloarthritides; Systemic lupus erythematosus; Systemic sclerosis; Unmet needs; Autoimmune Diseases; Clinical Trials as Topic; Disease Management; Humans; Quality Improvement; Rheumatic Diseases; Immunology and Allergy; Immunologymedicine.diseaseRheumatologyBiologic drugs treatment030104 developmental biologyautoimmune rheumatic diseasesPhysical therapyCLARITYSpondyloarthritidesbusinessWorking group
researchProduct

A Simple Method to Predict Blood-Brain Barrier Permeability of Drug- Like Compounds Using Classification Trees

2017

Background: To know the ability of a compound to penetrate the blood-brain barrier (BBB) is a challenging task; despite the numerous efforts realized to predict/measure BBB passage, they still have several drawbacks. Methods: The prediction of the permeability through the BBB is carried out using classification trees. A large data set of 497 compounds (recently published) is selected to develop the tree model. Results: The best model shows an accuracy higher than 87.6% for training set; the model was also validated using 10-fold cross-validation procedure and through a test set achieving accuracy values of 86.1% and 87.9%, correspondingly. We give a brief explanation, in structural terms, o…

0301 basic medicineQuantitative structure–activity relationshipComputer scienceDatasets as TopicQuantitative Structure-Activity Relationshipcomputer.software_genre01 natural sciencesPermeability03 medical and health sciencesMolecular descriptorDrug DiscoveryInternational literatureComputer SimulationTraining setDecision tree learningDecision Trees0104 chemical sciences010404 medicinal & biomolecular chemistry030104 developmental biologyPharmaceutical PreparationsBlood-Brain BarrierTest setData miningBlood brain barrier permeabilitycomputerAlgorithmsDecision tree modelMedicinal Chemistry
researchProduct

MODOMICS: a database of RNA modification pathways. 2017 update

2017

Abstract MODOMICS is a database of RNA modifications that provides comprehensive information concerning the chemical structures of modified ribonucleosides, their biosynthetic pathways, the location of modified residues in RNA sequences, and RNA-modifying enzymes. In the current database version, we included the following new features and data: extended mass spectrometry and liquid chromatography data for modified nucleosides; links between human tRNA sequences and MINTbase - a framework for the interactive exploration of mitochondrial and nuclear tRNA fragments; new, machine-friendly system of unified abbreviations for modified nucleoside names; sets of modified tRNA sequences for two bact…

0301 basic medicineRNA methylationBiologycomputer.software_genreMass Spectrometry03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRNA TransferEpitranscriptomicsTerminology as TopicRNA modificationDatabases GeneticGeneticsDatabase IssueHumanschemistry.chemical_classificationDatabase2'-O-methylationRNA030104 developmental biologyEnzymechemistry030220 oncology & carcinogenesisTransfer RNARNARibonucleosidesN6-MethyladenosinecomputerChromatography LiquidNucleic Acids Research
researchProduct

Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublis…

2018

Zofenopril is a lipophilic, sulfhydryl group-containing angiotensin-converting enzyme (ACE)-inhibitor, characterized by wide tissue distribution, long duration of action, and pleiotropic effects on endothelial dysfunction. Its clinical efficacy and safety have been described in the four randomized controlled trials of the SMILE program, which globally enrolled more than 3600 patients in post-acute myocardial infarction (AMI) setting. The SMILE-4 study specifically selected patients with left ventricular dysfunction at admission, and compared the effects of zofenopril or ramipril in combination with acetylsalicylic acid (ASA). Zofenopril demonstrated its superiority over ramipril in reducing…

0301 basic medicineRamiprilmedicine.medical_specialtyCaptoprilPopulationMyocardial InfarctionCardiologyAngiotensin-Converting Enzyme InhibitorsHeart failureReviewAcute myocardial infarction030204 cardiovascular system & hematologylaw.inventionZofenopril03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRandomized controlled trialDouble-Blind MethodRamiprillawInternal medicineAcute myocardial infarction; Angiotensin-converting enzyme inhibitors; Cardiology; Heart failure; Left ventricular dysfunction; Ramipril; Zofenopril; Pharmacology (medical)MedicineHumansPharmacology (medical)Myocardial infarctioneducationRandomized Controlled Trials as Topiceducation.field_of_studyLeft ventricular dysfunctionEjection fractionbusiness.industryGeneral Medicinemedicine.diseaseZofenopril030104 developmental biologyTreatment OutcomechemistryAngiotensin-converting enzyme inhibitorHeart failureCardiologyNumber needed to treatbusinessmedicine.drug
researchProduct

HUMAN T-LYMPHOTROPIC VIRUS 1 (HTLV-1) AND HUMAN T-LYMPHOTROPIC VIRUS 2 (HTLV-2): GEOGRAPHICAL RESEARCH TRENDS AND COLLABORATION NETWORKS (1989-2012)

2016

Publications are often used as a measure of research work success. Human T-lymphotropic virus (HTLV) type 1 and 2 are human retroviruses, which were discovered in the early 1980s, and it is estimated that 15-20 million people are infected worldwide. This article describes a bibliometric review and a coauthorship network analysis of literature on HTLV indexed in PubMed in a 24-year period. A total of 7,564 documents were retrieved, showing a decrease in the number of documents from 1996 to 2007. HTLV manuscripts were published in 1,074 journals. Japan and USA were the countries with the highest contribution in this field (61%) followed by France (8%). Production ranking changed when the numb…

0301 basic medicineResearch groupsBiomedical Researchlcsh:Arctic medicine. Tropical medicinelcsh:RC955-962030231 tropical medicinePopulationBibliometricsGlobal HealthGross domestic product03 medical and health sciences0302 clinical medicineHuman T-lymphotropic virus (HTLV)Global healthMedicineHumansCooperative BehaviorSocioeconomicseducationeducation.field_of_studyHuman T-lymphotropic virus 1biologyGeographybusiness.industryHuman T-lymphotropic virus 2Tropical spastic paraparesisGeneral Medicinebiology.organism_classificationHTLV-I InfectionsT cell leukemia/lymphoma030104 developmental biologyInfectious DiseasesGross national incomeBibliometricsHuman T-lymphotropic virus 1Human T-lymphotropic virus 2ImmunologyOriginal ArticlePeriodicals as TopicbusinessResearch collaboration
researchProduct

Biopiracy of natural products and good bioprospecting practice

2016

Made available in DSpace on 2018-11-26T16:27:45Z (GMT). No. of bitstreams: 0 Previous issue date: 2016-02-15 Deutsche Forschungsgemeinschaft Background: Biopiracy mainly focuses on the use of biological resources and/or knowledge of indigenous tribes or communities without allowing them to share the revenues generated out of economic exploitation or other non-monetary incentives associated with the resource/knowledge. Methods: Based on collaborations of scientists from five continents, we have created a communication platform to discuss not only scientific topics, but also more general issues with social relevance. This platform was termed 'PhytCancer -Phytotherapy to Fight Cancer' (www.phy…

0301 basic medicineResource (biology)Drug IndustryInternational CooperationTheftPharmaceutical ScienceIntellectual property0603 philosophy ethics and religionIndigenousPatents as Topic03 medical and health sciencesIndigenous knowledgeDrug DiscoveryPatents as TopicTraditional knowledgeDeveloping CountriesPharmacologyBioprospectingBiological ProductsBioprospectingPlants Medicinalbusiness.industryIntellectual propertyCommercializationOwnership06 humanities and the artsPublic relationsBioethicsNatural resource030104 developmental biologyIncentiveComplementary and alternative medicineEthnopharmacologyMolecular MedicinePatent060301 applied ethicsBusiness
researchProduct

Rev-Erb modulates retinal visual processing and behavioral responses to light

2016

International audience; The circadian clock is thought to adjust retinal sensitivity to ambient light levels, yet the involvement of specific clock genes is poorly understood. We explored the potential role of the nuclear receptor subfamily 1, group D, member 1 (REV-ERB; or NR1D1) in this respect. In light-evoked behavioral tests, compared with wild-type littermates, Rev-Erb(-/-) mice showed enhanced negative masking at low light levels (0.1 lx). Rev-Erb(-/-) mouse retinas displayed significantly higher numbers of intrinsically photosensitive retinal ganglion cells (ipRGCs; 62% more compared with wild-type) and more intense melanopsin immunostaining of individual ipRGCs. In agreement with a…

0301 basic medicineRetinal Ganglion CellsLight[SDV]Life Sciences [q-bio]Circadian clockelectroretinogramBiochemistrychemistry.chemical_compound0302 clinical medicinecircadian clockskin and connective tissue diseasesComputingMilieux_MISCELLANEOUSMice KnockoutipRGCsBehavior AnimalphotoreceptorsorganizationCircadian Rhythmmedicine.anatomical_structurerodtranscriptionBiotechnologyPhotopic visionMelanopsinnegative maskingrat retinaBiologyRetina03 medical and health sciences[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyCircadian ClocksGeneticsmedicineAnimalsCircadian rhythmScotopic visionmelanopsin-knockout miceMolecular BiologymouseRetinaIntrinsically photosensitive retinal ganglion cellsRod OpsinsRetinalganglion-cellsbody regionsmammalian retina030104 developmental biologychemistryNuclear Receptor Subfamily 1 Group D Member 1sense organsNeuroscience030217 neurology & neurosurgeryPhotic Stimulation[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Fragments of peer review: A quantitative analysis of the literature (1969-2015)

2018

This paper examines research on peer review between 1969 and 2015 by looking at records indexed from the Scopus database. Although it is often argued that peer review has been poorly investigated, we found that the number of publications in this field doubled from 2005. A half of this work was indexed as research articles, a third as editorial notes and literature reviews and the rest were book chapters or letters. We identified the most prolific and influential scholars, the most cited publications and the most important journals in the field. Co-authorship network analysis showed that research on peer review is fragmented, with the largest group of co-authors including only 2.1% of the wh…

0301 basic medicineScience and Technology WorkforceResearch Quality Assessmentlcsh:MedicineCareers in ResearchPeer review co-authorship collaboration communityCitation analysisCentralityData MiningSociologylcsh:ScienceMultidisciplinary05 social sciencesScientometricsco-authorshipResearch AssessmentKnowledge sharingProfessionsCitation AnalysiscommunityNetwork AnalysisResearch ArticleComputer and Information SciencesScience PolicyAbstracting and IndexingPeer ReviewAbstracting and Indexing as Topic ; Animals ; Data Mining ; Databases Bibliographic ; History 20th Century ; History 21st Century ; Humans ; Peer ReviewScopusLibrary science050905 science studiesResearch and Analysis MethodsHistory 21st Century03 medical and health sciencesAnimalsHumansScientific Publishinglcsh:RScientometricsHistory 20th CenturyDatabases Bibliographiccollaboration030104 developmental biologyQuantitative analysis (finance)People and PlacesScientistslcsh:QPopulation Groupings0509 other social sciencesScientific publishingCentrality
researchProduct

The role of molecular enrichment on future therapies in hepatocellular carcinoma

2017

Summary Hepatocellular carcinomas (HCCs) are characterised by considerable phenotypic and molecular heterogeneity. Treating HCC and designing clinical trials are particularly challenging because co-existing liver disease, present in most patients, limits aggressive therapeutic options. Positive results in recent phase III clinical trials have confirmed the high value of anti-angiogenic therapies for HCC in both first (sorafenib and lenvatinib) and second line (regorafenib and cabozantinib) treatment modalities. However, failure of several large randomised controlled clinical trials over the last 10 years underlines the necessity for innovative treatment strategies and implementation of tran…

0301 basic medicineSorafenibOncologymedicine.medical_specialtyCarcinoma HepatocellularCabozantinibPhases of clinical research03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineRegorafenibmedicineHumansMolecular Targeted TherapyClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsPrecision medicinemedicine.diseasedigestive system diseasesClinical trial030104 developmental biologychemistry030220 oncology & carcinogenesisHepatocellular carcinomaImmunotherapybusinessLenvatinibmedicine.drugJournal of Hepatology
researchProduct

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

2020

Proper trial design is critical for the success of clinical investigations. Hepatocellular carcinoma (HCC) is a complex disease that has several unique properties. In 2008, after the approval of sorafenib, a panel of experts proposed guidelines for trial design and endpoints in HCC that have been instrumental during the last decade and provided a framework to allow an homogeneous analysis of reported investigations. Since then, several phase III studies have been reported and novel challenges have emerged. A panel of experts conveyed by AASLD organized a Special Topic Conference on trial design and endpoints to address those emerging challenges. This review summarizes the analysis and concl…

0301 basic medicineSorafenibmedicine.medical_specialtyCarcinoma HepatocellularConsensusEndpoint DeterminationMEDLINEDisease03 medical and health sciences0302 clinical medicinemedicineHumansProgression-free survivalChemoembolization TherapeuticLiquid biopsyIntensive care medicineAdverse effectImmune Checkpoint InhibitorsProtein Kinase InhibitorsClinical Trials as TopicHepatologybusiness.industryLiver NeoplasmsLiquid Biopsymedicine.diseaseLiver TransplantationClinical trial030104 developmental biologyResearch DesignHepatocellular carcinoma030211 gastroenterology & hepatologybusinessmedicine.drugHepatology
researchProduct